BRAF and melanoma: Mutational activation of BRAF in mice carrying conditional melanocyte‐specific expression of BrafV600E (or the mouse equivalent, BrafV618E) has also been used to model melanoma development, tumour progression, and drug resistance 47, 48, 49.